Penumbra, Inc. $PEN Shares Sold by Savant Capital LLC

Savant Capital LLC decreased its stake in shares of Penumbra, Inc. (NYSE:PEN) by 3.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,612 shares of the company’s stock after selling 182 shares during the period. Savant Capital LLC’s holdings in Penumbra were worth $1,184,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in Penumbra by 437.0% during the 1st quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock worth $188,159,000 after purchasing an additional 572,606 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Penumbra in the 1st quarter valued at about $63,731,000. Los Angeles Capital Management LLC boosted its stake in shares of Penumbra by 487.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 179,550 shares of the company’s stock worth $48,013,000 after purchasing an additional 148,968 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Penumbra during the first quarter worth about $33,696,000. Finally, Woodline Partners LP raised its position in shares of Penumbra by 476.1% in the first quarter. Woodline Partners LP now owns 145,881 shares of the company’s stock valued at $39,010,000 after buying an additional 120,558 shares during the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Penumbra Price Performance

Shares of Penumbra stock opened at $280.92 on Thursday. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $310.00. The stock has a market capitalization of $11.00 billion, a P/E ratio of 74.71, a PEG ratio of 2.10 and a beta of 0.51. The company has a current ratio of 6.75, a quick ratio of 4.04 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $256.31 and its 200 day moving average price is $258.18.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analyst estimates of $340.77 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The firm’s revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.85 earnings per share. Penumbra has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 186 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $248.61, for a total value of $46,241.46. Following the completion of the sale, the director owned 8,702 shares of the company’s stock, valued at $2,163,404.22. This represents a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Adam Elsesser sold 15,900 shares of Penumbra stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $254.53, for a total transaction of $4,047,027.00. Following the transaction, the chief executive officer owned 170,280 shares in the company, valued at $43,341,368.40. The trade was a 8.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 34,430 shares of company stock worth $9,008,613. 5.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PEN has been the topic of a number of analyst reports. BTIG Research restated a “buy” rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, October 27th. Wall Street Zen cut Penumbra from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. UBS Group set a $335.00 price objective on Penumbra and gave the company a “buy” rating in a research report on Wednesday, July 30th. JPMorgan Chase & Co. increased their target price on Penumbra from $265.00 to $275.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, Truist Financial decreased their price target on Penumbra from $310.00 to $300.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.69.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.